Certolizumab pegol (CDP 870) is a PEGylated fragment of a humanised anti-TNF-α monoclonal antibody (MAb) in late-stage development for Crohn’s disease (CD) and rheumatoid arthritis (RA), and in Phase II trials for psoriasis.